The company provides more than 1500 kinds of diagnostic and research ready-to-use antibodies and concentrated antibodies, a complete range of immunology and molecular pathology reagents, and also acts as an agent for thousands of imported antibodies and supporting reagents. We are the sole agent of Labvision immunohistochemistry automatic staining system in mainland China, and provide all-round technical support and service.
In the past ten years, adhering to the philosophy of "professionalism, truth-seeking, and enterprise", Myson has always been committed to providing users with high-quality products synchronized with the world, and established China's first immunohistochemistry quality control laboratory, which has vigorously promoted the development of China's pathology and biology. The original academic marketing, strictly controlled product quality and perfect after-sales service have made Myson one of the leading biomedical reagent suppliers in China, and its immunohistochemistry reagents have been ranked the first in the domestic market share for many years.
The full completion of the Human Genome Project signifies that we are about to enter a new biological era. Maisin will continue to provide Chinese scientists with high-quality products and a full range of technical support and services, and make its own contribution to the cause of human health. In March 1993, Mysin was founded in Hongshan Science and Technology Park, Fuzhou, with a registered capital of 500,000 RMB;
In January 1994, Mysin launched the immunohistochemistry ready-to-use antibody for the first time in China;
In June 1994, Mysin launched the ready-to-use SP enzyme labeling kits for the first time, with a shelf-life of 12 months, which has reached the international advanced level;
In April 1994, the company entered into an agreement with the Chinese Society of Pathology, the Chinese Association of Pathologists, and the Chinese Association of Biological Sciences, to provide high-quality products and comprehensive technical support and services to make contributions to human health. In April 1994, Maixin cooperated with Chinese Pathology Association and Chinese Pathology Association Journal to hold the "National Symposium on New Technology and New Progress in Pathology and Immunohistochemistry Technology" in Fuzhou for the first time;
In 1995, Maixin was awarded the honorary title of "High and New Technology Enterprises in Fujian Province"
In 1996, Maixin was invited to attend the "Fujian Provincial High-Tech Enterprises" seminar in Fuzhou, China. In 1996, Maixin was invited to participate in the First National Immunohistochemistry Standard Seminar held in Beijing and made a speech at the conference;
In May 1997, Maixin initiated the organization and participated in the preparation of the first immunohistochemistry diagnostic monograph, "Diagnostic Immunohistochemistry," was published;
In 1998, Maixin set up a web site and registered the company's domain name in Chinese and English, and at the same time, also registered the English "Immunohistochemistry". "Immunohistochemistry" and "Antibody" are two domain names, which made the click rate of the company's website increased significantly;
In 1999, Maixin's trademark was successfully registered by the State Trademark Office, which is subject to national laws and regulations. In September 2000, Chen Mingyi, former Secretary of Fujian Provincial Party Committee, Pan Xincheng, Vice Governor of Fujian Province and other provincial and municipal leaders visited Maixin and highly affirmed the development of Maixin;
In 2001, Maixin entered into a strategic alliance with LabVision, the world's largest supplier of automated immunohistochemistry instruments;
In 2001, Maixin entered into a strategic alliance with LabVision, the world's largest supplier of automated immunohistochemistry instruments.
In 2001, MaxicoM published the first colorful immunohistochemistry antibody catalog in the industry, and has published the fifth catalogue continuously since then;
In 2002, the National Immunohistochemistry Staining Competition hosted by MaxicoM was held in Wuyi Mountain, Fujian Province;
In 2003, the company successfully injected capital and registered as a registered company, and was highly affirmed the development of the company;
In 2003, the company successfully injected capital and registered as a registered company. In 2003, the company's capital injection was successful, and the registered capital reached 3.5 million RMB;
In 2003, the rabbit monoclonal antibody immunohistochemistry reagent was introduced and developed for the first time in China;
In 2003, Mr. Wang Xiaoya, the general manager of Maishin, led the heads of the relevant departments of Maishin to visit the U.S.A., and formed a strategic alliance with LabVision;
In 2003, Maisin wholly funded the inaugural meeting of CCP (Chinese Pathologists Committee) in Hainan;
In 2005, Maisin cooperated with foreign laboratories and successfully developed a polymer-based non-biotin immunohistochemistry enzyme amplification system;
In 2006, Maisin was granted a free subsidy from the Small and Medium-sized Enterprises Innovation Funds of the Ministry of Science and Technology of the People's Republic of China for the prostate double-staining and triple-labeling test kits, which were highly evaluated by experts. In August 2006, the "Pathology Forum at Home and Abroad" was held in Fuzhou, which was hosted by Maxim;
In 2007, Max007, Maxim's original immunohistochemistry amplification system with high amplification and sensitivity, was successfully developed;
The first color immunohistochemistry amplification system in China was developed in 2007, which was the first color immunohistochemistry amplification system in China;
In 2007, the first color immunohistochemistry amplification system in China was successfully developed in China. In 2007, the first color immunohistochemistry monograph "Immunohistochemistry Pathology Diagnosis" was published by Maxim's wholly-owned sponsorship;
In 2007, Maxim's purification laboratory construction was completed, and the GMP renovation system was successfully certified by the Fujian Provincial Food and Drug Administration;
July 2007, Maxim's 13 immunohistochemistry kits passed the certification of China Pharmaceutical Biologics Appraisal Institute (CPBAI) for the first time in China. In July 2007, 13 kinds of immunohistochemistry kits of Maixin passed the test of China Pharmaceutical and Biological Products Identification Institute for the first time in China;
In November 2007, Maixin successfully increased its capital again, and the registered capital reached 20 million RMB;
In 2008, the five-year National Immunohistochemistry Quality Control Activity supported by Maixin was successfully completed;
In 2009, Maixin's trademark was awarded as "Famous Trademark of Fujian Province". Famous Trademark of Fujian Province", and in the same year, the company was awarded the honorary title of "High-tech Enterprise of Fujian Province" again;
In 2009, we set up a special fund for pathology for the first time in the country, which is called "Maixin-Pathology" fund, to support scientific and technological personnel.
In 2009, the company set up a special pathology fund "Maixin - Pathology" for the first time in China, to support scientific and technological personnel to carry out in-depth research on immunohistochemistry, standardization and popularization of education;
In 2009, the company successfully increased its capital again, and the registered capital reached 30 million RMB.